Itacitinib Clinical Trials (2026): 50 Studies for Hematologic and Lymphocytic Disorder & Solid Tumors

Where to Participate: All Itacitinib Trial Sites in the U.S. (4 sites across 4 states)

Every actively recruiting Itacitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Itacitinib clinical trials at a glance: phase × recruitment status

Recruiting Itacitinib clinical trials (3)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

Itacitinib clinical trials by indication

Itacitinib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Terminated and withdrawn Itacitinib trials (18)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

• NCT04239989terminatedItacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant
• NCT05660421withdrawnItacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
• NCT03670069terminatedItacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
• NCT03584516terminatedGRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
• NCT03978637terminatedSafety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
• NCT04200365terminatedA Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
• NCT04446182terminatedItacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD
• NCT03320642terminatedGRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
• NCT04070781terminatedItacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
• NCT03425006terminatedPembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
• NCT04220632terminatedA Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
• NCT04127721withdrawnItacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
• NCT03721965terminatedSafety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
• NCT03627052withdrawnA Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
• NCT02559492terminatedItacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
• NCT02456675terminatedINCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
• NCT02257619terminatedStudy of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
• NCT02355431withdrawnItacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

All Itacitinib trials (50)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Itacitinib clinical trials: frequently asked questions

How many Itacitinib clinical trials are there?

50 Itacitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 21 are marked completed.

Are Itacitinib clinical trials recruiting in 2026?

Yes — 3 Itacitinib trials are actively recruiting in 2026, with 4 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Itacitinib being studied for?

Itacitinib is being studied for Hematologic and Lymphocytic Disorder, Solid Tumors, B-Cell Malignancies, Non Small Cell Lung Cancer, NSCLC (Non-small Cell Lung Carcinoma) and 90 more. The trials are grouped by indication on this page.

What phase is Itacitinib in?

Itacitinib clinical trials span 1 Phase 3, 25 Phase 2, 13 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Itacitinib clinical trials?

The lead sponsor across the most Itacitinib trials is Incyte Corporation, with 17 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Itacitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.